Skip to main content

Genewiz, BeiGene Collaborate on Cancer Biomarker Discovery

NEW YORK (GenomeWeb News) – Genewiz today announced a deal with BeiGene for the use of Genewiz's cancer panels to accelerate cancer biomarker discovery.

Under the terms of the deal, Beijing-based BeiGene will use Genewiz's OncoGxOne Discovery cancer panels to identify and elucidate genetic variations in cancers that are prevalent in China and the Asia-Pacific region.

Financial and other terms of the deal were not disclosed.

"Our collaboration with Genewiz and application of the OncoGxOne(TM) cancer panels will enable characterization of primary tumor models at the genetic level, with a focus on aberrations in cancer related genes," Lai Wang, head of Discovery Biomarkers for BeiGene, said in a statement. BeiGene is a life science biotech firm focused on developing oncology drugs.

The deal is the second by South Plainfield, N.J.-based Genewiz in recent weeks aimed at the Chinese market. In late June it and KeyTest Diagnostics announced a collaboration to develop molecular diagnostics for that market.

Also, Genewiz and the John Theurer Cancer Center at Hackensack University Medical Center last month said they were collaborating on discovering ovarian cancer biomarkers.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.